RxDoctor Payments Data

Mark Bigler, MD

Urology · Bowling Green, KYNPI 1073517066

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.7% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,371, 6.4 times the $214 reported in 2019.

$5,207in general payments, 2019–2025

Across 267 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$833
  • Johnson & Johnson$437
  • AbbVie$420
  • Accord Healthcare, Inc.$380
  • Sumitomo Pharma America, Inc.$347
  • Urogen Pharma, Inc.$282
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$4,72391%
  • Education$4849%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,207 in reported general payments places this provider in the 65th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$326,863
Medicare patients
874
Services billed
18,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix35$92,813
CasodexBicalutamide12$37,184
MyrbetriqMirabegron33$17,819
GemtesaVibegron17$8,090
Finasteride387$4,551
Tamsulosin Hcl309$3,156
Estradiol17$2,384
Dutasteride57$1,634
Alfuzosin Hcl ErAlfuzosin Hcl90$1,613
CefuroximeCefuroxime Axetil221$1,258
NitrofurantoinNitrofurantoin Macrocrystal23$571
Trimethoprim14$472
Oxybutynin Chloride ErOxybutynin Chloride23$326
Ciprofloxacin Hcl145$237
Solifenacin Succinate17$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$347$100,90352 claims
Astellas Pharma US IncMyrbetriq$833$17,81933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 139 urology providers in Kentucky.

Other urology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →